Innovent’s Sintbilo cuts LDL by up to 65% as it targets first-line monotherapy label
Innovent’s Sintbilo cut LDL by about 64% to 65% without other lipid-lowering drugs, supporting a planned Chinese filing for monotherapy use.
Pharma & Biotech